Company profile: Barinthus Bio
1.1 - Company Overview
Company description
- Provider of clinical-stage immunotherapeutics and vaccines for infectious diseases and cancer, leveraging proprietary ChAdOx1/ChAdOx2 adenoviral vectors and MVA platforms to prime disease-specific T cells. Pipeline includes VTP-300 for chronic Hepatitis B, VTP-850 for prostate cancer, VTP-1000 for celiac disease, and the SNAP-TI platform to promote immune tolerance.
Products and services
- ChAdOx1 and MVA Platforms: Proprietary vectored platforms optimized to prime disease-specific T cells, used sequentially to enhance T cell immunity against chronic infectious diseases and cancer
- SNAP-TI: Tolerogenic platform engineered to deliver antigens in a context that promotes immune tolerance, aiming to restore immune balance in autoimmune and inflammatory diseases
- VTP-300: Vectorized immunotherapeutic candidate for chronic Hepatitis B, using ChAdOx and MVA vectors to induce sustained reductions in Hepatitis B surface antigen
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Barinthus Bio
Cellcentric
HQ: United Kingdom
Website
- Description: Provider of clinical-stage biotechnology therapies targeting p300/CBP inhibition to treat specific cancers, particularly solid tumors; developing the oral drug Inobrodib, currently in Phase I/II trials, with potential utility in non-small cell lung, breast, colon cancers and multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellcentric company profile →
Kura Oncology
HQ: United States
Website
- Description: Provider of precision medicines for solid tumors and blood cancers, advancing investigational therapies including ziftomenib for AML with specific mutations, tipifarnib for HRAS-mutant head and neck squamous cell carcinoma and other cancers, and KO-2806, a next-generation FTI for advanced solid tumors; also conducts clinical trials and offers expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kura Oncology company profile →
Kiyatec
HQ: United States
Website
- Description: Provider of ex vivo 3D cell culture technology that uses a patient's own living tumor cells to create functional microtumor models for testing cancer therapies and predicting response. Offers 3D Predict Glioma and 3D Predict Oncology, patient-specific microtumor creation (up to 1,000) for drug testing, and a HIPAA-compliant portal delivering patient-specific reports within 7-10 days to aid treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kiyatec company profile →
Kuur Therapeutics
HQ: United Kingdom
Website
- Description: Provider of off-the-shelf engineered CAR-NKT cell therapies, combining the natural biology of natural killer T cells with innovative CAR constructs for cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kuur Therapeutics company profile →
Cellinfinity Bio
HQ: United States
Website
- Description: Provider of a machine-learning-driven genome editing platform and engineered cell therapies. Offers CLASH to enable precise, replicable site-specific edits across up to 20,000 genes to discover enhancements for cell therapy; HYPERBOOSTS (gain-of-function) and ENDOMODS (loss-of-function) genes; OPTI-CARS CAR design optimizations; and Supercharged Cell Therapy CAR-T and CAR-NK cells enhanced for potency, persistence, penetration, and memory against solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellinfinity Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Barinthus Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Barinthus Bio
2.2 - Growth funds investing in similar companies to Barinthus Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Barinthus Bio
4.2 - Public trading comparable groups for Barinthus Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →